Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Other Operating Expenses (2018 - 2025)

10x Genomics' Other Operating Expenses history spans 7 years, with the latest figure at $76.6 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses changed N/A year-over-year to $76.6 million; the TTM value through Dec 2025 reached $266.2 million, changed N/A, while the annual FY2025 figure was -$49.9 million, N/A changed from the prior year.
  • Other Operating Expenses for Q4 2025 was $76.6 million at 10x Genomics, up from $75.4 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $83.3 million in Q1 2023 and bottomed at -$850000.0 in Q2 2021.
  • The 4-year median for Other Operating Expenses is $66.7 million (2022), against an average of $50.5 million.
  • The largest annual shift saw Other Operating Expenses plummeted 101.9% in 2021 before it surged 34992.11% in 2022.
  • A 4-year view of Other Operating Expenses shows it stood at -$850000.0 in 2021, then skyrocketed by 9380.82% to $78.9 million in 2022, then crashed by 75.18% to $19.6 million in 2023, then soared by 291.34% to $76.6 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Other Operating Expenses are $76.6 million (Q4 2025), $75.4 million (Q3 2025), and $33.7 million (Q2 2025).